61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date
- Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across several NRG1+ tumor types (29%)- Zenocutuzumab continues to be well tolerated with a favorable safety profile
- Company to host investor call to discuss interim clinical results and provide a program update on Sunday, June 6 at 6:00 PM ET
Company Conference Call and Webcast Information
Merus will hold a conference call and webcast for investors on Sunday, June 6, 2021 at 6:00 PM ET to discuss the Zeno clinical data. A replay will be available after the completion of the call in the Investors and Media section of our website.
Date: Sunday, June 6 at 6:00 pm ET
Webcast link: available on our website
Dial-in: Toll-Free: 1-877-260-1463 / International: 1-706-643-5907
Conference ID: 9678617
https://finance.yahoo.com/news/merus-presents-clinical-data-zenocutuzumab-160000708.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.